Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AICs). Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase approved for the treatment of relapsed CLL and CLL with del(17p). The effect of ibrutinib treatment on the incidence of AIC is currently unknown. We reviewed medical records of 301 patients treated with ibrutinib, as participants in therapeutic clinical trials at The Ohio State University Comprehensive Cancer Center between July 2010 and July 2014. Subjects were reviewed with respect to past history of AIC, and treatment-emergent AIC cases were identified. Before starting ibrutinib treatment, 26% of patients had experienced AIC. Information was available for a total of 468 patient-years of ibrutinib exposure, during which there were six cases of treatment-emergent AIC. This corresponds to an estimated incidence rate of 13 episodes for every 1000 patient-years of ibrutinib treatment. We further identified 22 patients receiving therapy for AIC at the time ibrutinib was started. Of these 22 patients, 19 were able to discontinue AIC therapy. We found that ibrutinib treatment is associated with a low rate of treatment-emergent AIC. Patients with an existing AIC have been successfully treated with ibrutinib and subsequently discontinued AIC therapy.
INTRODUCTION
Autoimmune cytopenias (AICs) complicate the disease course of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in 10-25% of cases longitudinally over the course of disease. 1, 2 This can occur at any time, but most often is noted during times when CLL is clinically active. 2, 3 Autoimmune hemolytic anemia (AIHA) is the most common AIC observed, followed by immune thrombocytopenia (ITP). Pure red cell aplasia and autoimmune granulocytopenia are seen only rarely. 2, 3 These secondary AIC require treatment with immunosuppression, which adds to the treatment burden, morbidity and sometimes mortality experienced by CLL patients. [3] [4] [5] AIC in some cases can be triggered by treatment with standard therapies, notably chemotherapeutic agents such as fludarabine. 2, 6, 7 Although this risk with fludarabine can be abrogated by use in combination with cyclophosphamide, understanding the relationship of any new CLL-targeted treatment with AIC remains imperative. [8] [9] [10] Inhibitors of Bruton's tyrosine kinase (BTK) are an important new class of targeted agents approved for the treatment of CLL as well as other lymphoid malignancies. BTK is a critical molecule in the B-cell receptor signaling pathway. BTK inhibitors effectively abrogate B-cell receptor and integrin signaling, and are highly effective in the treatment of CLL. [11] [12] [13] The first-in-class agent ibrutinib was approved in 2014 by the United States Food and Drug Administration for the treatment of CLL patients who have received previous treatment or who have the high-risk cytogenetic feature of deletion 17p. 14 Ibrutinib is now in widespread clinical use, and as the drug is currently administered continuously until disease progression, the prevalence of ibrutinib use over time will continue to increase.
The effects of ibrutinib treatment on the natural history of AIC have not yet been characterized. We conducted a retrospective cohort review of patients treated with ibrutinib for CLL or SLL to determine the incidence of AIC during treatment and describe the course of patients with a history of AIC, including those on chronic AIC therapy.
MATERIALS AND METHODS
Patients who received ibrutinib at The Ohio State University Comprehensive Cancer Center on four sequential completed clinical trials with enrollment from July 2010 to July 2014 were included in this analysis. All studies were approved by the appropriate institutional review board. The treatment schemas for these trials are shown in Table 1 . In three of these studies patients received single agent ibrutinib, whereas in one study enrolling a minority of the patients (21%), ibrutinib was given in combination with ofatumumab.
All patients who received at least one dose of ibrutinib were included in these analyses. The diagnosis of AIC was made by the treating physician but was not independently verified. Diagnoses of AIHA, ITP and pure red cell aplasia were considered as AIC. Autoimmune granulocytopenia was not included owing to the rarity of the condition, difficulty in confirming this diagnosis and previously described relationship to treatment with anti-CD20 monoclonal antibodies. [15] [16] [17] Treatment-emergent AICs were defined as episodes occurring any time between the first and last doses of ibrutinib received; were considered new if the type had never before been experienced by that patient, even if the patient had an antecedent AIC of a different type; and were classified as relapsed if the same type had been experienced by a patient before starting ibrutinib.
Patient characteristics were summarized with descriptive statistics and compared between those who had and had not previously experienced AIC, using Fisher's exact test or the Wilcoxon rank sum test. All tests were two sided and statistical significance was declared at α = 0.05. The persontime incidence rate of treatment-emergent AIC events was estimated by dividing the number of AIC episodes observed while on ibrutinib therapy by the total number of years patients were receiving ibrutinib and were at risk. The incidence rate is presented as the number of occurrences per 1000 patients per year (that is, per 1000 person-years). Differences in incidence rates between subgroups were estimated with 95% confidence intervals (CIs) and compared using the person-time χ 2 -test. 18 Among the 22 patients who were on chronic AIC therapy at the time of beginning ibrutinib, time to discontinuation of AIC therapy was calculated from the date of first ibrutinib treatment to the date of discontinuation (event) or date last known to be on AIC therapy (censored). Median time to discontinuation was estimated using the method of Kaplan-Meier. Last follow-up was in July of 2014 for all patients except those on a chronic AIC therapy who underwent~6 additional months of follow-up to monitor their chronic AIC therapy use.
RESULTS

Cohort characteristics
A total of 301 patients treated with ibrutinib were identified. Baseline characteristics of the cohort can be found in Table 2 . The study cohort included primarily patients with relapsed CLL and was relatively enriched for CLL disease features associated with AIC including complex karyotype, deletion 17p and unmutated immune globulin heavy chain gene status. [19] [20] [21] [22] Before starting ibrutinib, 26% (78/301) of patients had experienced an episode of AIC. Of patients who had a history of AIC, 44 (56%) had AIHA, 25 (32%) had ITP, 8 (10%) had both AIHA and ITP either concomitantly or sequentially, and 1 (1%) had pure red cell aplasia. They were treated with a variety of AIC therapies with many patients receiving multiple therapies. These AIC therapies are found in Table 3 .
Characteristics were not significantly different between patients who had previously experienced AIC and those who had not, except for a positive direct anti-globulin test (DAT) at study entry. A DAT was not required for all studies, but was available for 252 patients. In those patients a positive DAT was more common in the group who had previously experienced AIC (40%) compared with those who had not (8%; P o 0.0001).
With a median follow-up of 1.8 years (range 0.2-4.1), 216/301 (72%) patients remained on ibrutinib therapy. The median time to discontinuation had not been reached.
Patients receiving AIC therapy at ibrutinib initiation Of the 78 patients with a history of AIC, 22 (28%) were receiving AIC therapy when ibrutinib was started, although all had controlled disease. One study (OSU 12024) specifically excluded patients with uncontrolled AIHA or ITP defined as those requiring 420 mg of prednisone daily or equivalent dose of steroids or declining hemoglobin or platelet count due to immune destruction. The remaining studies functionally excluded uncontrolled AIC by excluding immune therapies or cytopenias not related to CLL infiltration of bone marrow.
In the group of patients taking an AIC therapy at the time ibrutinib was started, the majority of patients had only experienced one prior AIC episode (12/22, 55%). An additional five patients had experienced two episodes, two had three prior episodes, and one patient each had four, five and six prior episodes. Median time from the first AIC episode to start of ibrutinib treatment was 14.6 months (range 0.3-85.0), and these patients had been on continuous AIC therapy for a median of 2.9 months (range 0.3-34.2). Of these patients, 14 (64%) were receiving prednisone alone, 3 (14%) were receiving prednisone plus cyclosporine, 2 (9%) romiplostim, 2 (9%) cyclosporine and 1 (5%) monthly rituximab. The patient on monthly rituximab discontinued this treatment upon starting ibrutinib and did not experience an AIC relapse. AIC therapy was discontinued in 86% of patients at an estimated median of 4.7 months (95% CI: 0.7-7.4) from ibrutinib initiation. Time to AIC therapy discontinuation was variable and is shown in Figure 1 along with the timing of AIC episodes in relation to ibrutinib treatment. Three patients were known to be on an AIC therapy at the last time treatment records were available. One patient with ITP remained on 2.5 mg of prednisone daily and was censored at last follow-up. Two others were censored once AIC treatment records were no longer available. Only one patient with a history of refractory AIHA experienced a relapse after discontinuing chronic AIC therapy with prednisone 3 weeks into ibrutinib treatment. He was unable to remain on ibrutinib owing to high-dose steroid treatment for AIHA and recurrent infections.
Treatment-emergent AIC Six cases of treatment-emergent AIC were identified over a total of 468 patient-years of ibrutinib exposure, corresponding to an estimated incidence rate of 13 (95% CI: 3-23) AIC episodes per 1000 patient-years of ibrutinib exposure. Of these episodes, three were new and three were relapses (Table 4) . Only one episode occurred in the group receiving concomitant anti-CD20 monoclonal antibody treatment estimating an incidence rate of 7 (95% CI: 0-21) AIC episodes per 1000 patient-years of ibrutinib treatment in this group, compared with an estimated 15 (95% CI: 2-29) AIC episodes per 1000 patient-years in the ibrutinib monotherapy group. Given the rarity of these events and with observation over a limited period of time, the difference in rates did not demonstrate statistical significance.
All treatment-emergent AIC patients received treatment with single agent ibrutinib except one who received ibrutinib in combination with ofatumumab. The patients were diverse in terms of age (range 53-77 years old), Rai stage (range I-IV) and number of prior CLL treatments (range 0-6). AIC episodes did not appear to be temporally associated with ibrutinib initiation, occurring at 0.2, 1, 6, 7.5, 22 and 23 months after the first dose of ibrutinib. The treating physician suspected that the episode of AIHA diagnosed 1 week after starting ibrutinib may have antedated ibrutinib initiation, but confirmatory laboratory testing was not available.
Treatment-emergent cases received AIC therapy with corticosteroids, intervenous immune globulin or both. Ibrutinib treatment was temporarily suspended in four of the six cases to allow for doses of prednisone excluded by the clinical trial protocol. Patients restarted ibrutinib once steroid dose was lowered to the permitted level. The three patients who subsequently discontinued ibrutinib did so for reasons that were not directly related to their AIC. Two patients died from infections and one had a rash, which may have been unrelated to study or AIC treatment. Of the three patients able to continue ibrutinib, all recovered and AIC therapy was able to be discontinued without relapse.
Of note, the patient who received combination ofatumumab and ibrutinib treatment and experienced a relapse of AIHA developed isolated neutropenia 6 months after starting ibrutinib (8 months after starting ofatumumab). His neutropenia was initially treated with granulocyte colony-stimulating factor and a bone marrow biopsy demonstrated improvement in CLL (60-70% CLL before therapy vs 30% on ibrutinib). There was no morphologic evidence of myelodysplastic syndrome and karyotype and FISH panel were unchanged from study entry. A monoclonal T-cell population was identified by PCR and he was started on cyclosporine with improvement in the neutropenia. The diagnosis of autoimmune granulocytopenia or late-onset neutropenia after anti-CD20 monoclonal antibody therapy was considered. Later in his ibrutinib treatment course he was Figure 1 . Relationship of AIC episodes and therapy to ibrutinib treatment. Time from the start of most recent AIC therapy to AIC therapy discontinuation is shown for the 22 patients who were on a continuous AIC therapy at the time of starting ibrutinib. All AIC episodes experienced by these patients are shown. Two patients were censored when they were no longer followed for their AIC therapy. One patient was censored at the last follow-up when known to be taking prednisone. *Episode of AIHA treated with steroids, with a second episode after ibrutinib was discontinued. **Episode of ITP treated with intervenous immune globulin.
successfully treated for a relapse of his AIHA with intervenous immune globulin without discontinuing ibrutinib. At last follow-up he remained on cyclosporine and ibrutinib with a normal neutrophil count and no evidence of hemolysis.
DISCUSSION
Here we provide the first detailed description of the incidence and outcomes of AIC in patients receiving ibrutinib. This adds to previous abstracts by our group and others. 23, 24 Our study cohort was at increased risk for the development of AIC given the long median duration of CLL, high median number of prior therapies and relatively high percentage of patients with unmutated immune globulin heavy chain gene. As an indicator of this risk, 26% of the patients had experienced at least one episode of AIC before study enrollment, which is one of the higher reported AIC rates in studies of CLL patients. 2, 25 Despite this, a low rate of treatment-emergent AIC was seen, suggesting that ibrutinib reduces the risk of AIC development.
There are several mechanisms of AIC development specific to CLL, which are potentially targeted by ibrutinib. First, any treatment that is able to control the CLL clone will reduce secondary AIC. In AIHA, the leukemic cells have been demonstrated to be more efficient at presenting Rh antigens than other antigen-presenting cells. 26 Reduction in the ability of the CLL cells to perform this function by effective therapeutic treatment with ibrutinib would reduce Rh antigen presentation and therefore AIC. Beyond that, it is known that in the majority of cases of AIHA and ITP the pathogenic antibody is an IgG produced by non-leukemic poly-or oligoclonal 'bystander' B cells. 27 By inhibiting B-cell receptor signaling, the ability of these non-leukemia B cells to respond to autoantigens and produce the pathologic antibody may be inhibited, halting antibody-mediated AIC. This mechanism is less clearly implicated in pure red cell aplasia or autoimmune granulocytopenia that is not mediated by an antibody. Ibrutinib has the potential to inhibit AIC mechanisms beyond its effect on B cells. The environment of immune dysregulation in CLL has a role in AIC development with changes in T-cell subsets associated with AIC development. 28 Ibrutinib can impact this with inhibition of ITK, which could diminish response of auto-reactive T cells. In addition, ibrutinib has been shown to shift T helper immunity toward a Th1 response that is less favorable for the development of AIHA, which primarily exhibits Th2. 29, 30 Finally, ibrutinib may reduce clearance of antibody-coated cells from circulation by decreasing the function of the reticuloendothelium. This has not yet been demonstrated, but ibrutinib does alter macrophage function. 31 If our findings are reinforced in laboratory models and prospective clinical study, ibrutinib would represent a therapeutic alternative to existing therapies for AIC.
Our analysis is limited by the retrospective design. Many of the patients did not receive medical care at our institution from the time of their initial CLL diagnosis, and therefore incomplete records may underestimate the incidence of historical AIC. As well, patients were prospectively followed for ibrutinib efficacy and safety and not specifically for AIC, so new AIC diagnoses were not always extensively evaluated, potentially over-or underestimating the incidence of treatment-emergent AIC. However, given that ibrutinib is relatively new to clinical practice and our center has a large cohort of patients with long follow-up, more robust data will not likely be available for a long period of time. There is also a possibility of ascertainment bias as patients with active AIC were excluded from enrollment on the included clinical trials. However, given the number of patients with prior AIC episodes, receiving ongoing AIC treatment when starting ibrutinib or experiencing an episode of AIC in the months before starting ibrutinib as shown in Figure 1 , we would still anticipate a much higher incidence rate than we report.
Ibrutinib is already changing the way CLL is treated by providing effective treatment that is tolerable and avoids the risks of conventional chemotherapy. As CLL treatment moves away from chemotherapy and more patients receive ibrutinib, additional benefits in terms of immune modulation can be realized. At a minimum, we offer preliminary evidence that the control of AIC may be an important secondary benefit of ibrutinib that can assist in selection of appropriate patients for this treatment. Given the cost and indefinite duration of treatment, ibrutinib is unlikely to replace steroids as a first-line AIC therapy. However, ibrutinib may offer a new therapeutic option for AIC patients with concomitant treatment indications for their underlying CLL, refractory AIC or experiencing toxicities from long-term immunosuppressant therapy should our findings be confirmed in future prospective clinical trials in this patient population.
We showed an absolute difference in the incidence rates of AIC episodes during ibrutinib treatment compared with treatment with ibrutinib and ofatumumab with a trend toward lower rates in the combination arm. This difference did not reach statistical significance owing to the rarity of AIC events and may reach significance with longer-term follow-up or a larger sample size. Although the addition of anti-CD20 monoclonal antibodies has not been proven to increase the efficacy of ibrutinib treatment for CLL, the combination may have a benefit as AIC therapy in select patients.
In conclusion, ibrutinib may have an immune-stabilizing effect, which precludes the development of new AIC and facilitates discontinuation of chronic AIC therapies. This information is potentially significant for CLL patients taking or considering ibrutinib treatment, including those with a history of AIC where our findings do not show a high rate of AIC relapse. The effect of ibrutinib on AIC, which we observed, warrants further investigation in prospective clinical trials, particularly for patients with refractory AIC or those experiencing toxicities from long-term immunosuppression where there is an unmet clinical need for new therapies.
CONFLICT OF INTEREST
JAJ has served as a consultant for Pharmacyclics and Janssen. KJM has received research support from Pharmacyclics. KAB has received research funding from Pharmacyclics and Janssen. SMJ has received research funding and has served as a consultant for Pharmacyclics. The remaining authors declare no conflict of interest.
